Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the ...
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK ...
Since anti-CD20 monoclonal antibodies are used for more indications today and are supposed to be used even more in the future, LON is anticipated to be a clinical problem encountered in many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback